ChemoCentryx, Inc. Cancels IPO  
11/16/2008 1:16:09 AM

PeHUB -- ChemoCentryx Inc., a Mountain View, Calif.-based developer of oral drugs for autoimmune diseases, inflammatory diseases and oncology, has withdrawn registration for a $57.5 million IPO, citing “market conditions.” The company had planned to trade on the Nasdaq, with Credit Suisse serving as lead underwriter.